Utah Medical Products, Inc. added Kevin C. Timken, Esq. to its Board of Directors. Timken, who served as the company’s outside legal counsel for more than twenty years, brings expertise in FDA and SEC compliance.
The appointment expands the board’s legal and regulatory capabilities and follows the company’s long‑standing practice of maintaining a seasoned board, whose average tenure is 27.8 years.
In the same announcement, Utah Medical Products approved a quarterly cash dividend of $0.31 per share, a 1.6% increase over the prior dividend. The dividend will be payable on January 5, 2026, to shareholders of record as of December 16, 2025.
Utah Medical Products develops and markets specialty medical devices for women and babies, with products sold in more than 100 countries. The company’s market capitalization is $187.41 million and it trades on the NASDAQ exchange.
Financially, the company has a price‑to‑earnings ratio of 16.82, a return on equity of 10%, and a current ratio of 32.06, indicating strong liquidity and a cash‑rich balance sheet.
The dividend yield stands at 2.09%, reflecting the company’s long‑term commitment to returning value to shareholders.
Utah Medical Products has paid dividends for 22 consecutive years, underscoring its commitment to shareholder returns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.